Cargando…

MRI-based classification of IDH mutation and 1p/19q codeletion status of gliomas using a 2.5D hybrid multi-task convolutional neural network

BACKGROUND: IDH mutation and 1p/19q codeletion status are important prognostic markers for glioma that are currently determined using invasive procedures. Our goal was to develop artificial intelligence-based methods to noninvasively determine molecular alterations from MRI. METHODS: Pre-operative M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chakrabarty, Satrajit, LaMontagne, Pamela, Shimony, Joshua, Marcus, Daniel S, Sotiras, Aristeidis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Basic and Translational Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10162113/ https://www.ncbi.nlm.nih.gov/pubmed/37152810 http://dx.doi.org/10.1093/noajnl/vdad023

Ejemplares similares

Frequency of false-positive FISH 1p/19q codeletion in adult diffuse astrocytic gliomas
por: Ball, Matthew K, et al.
Publicado: (2020)

FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas
por: Sharaf, Radwa, et al.
Publicado: (2021)

IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas
por: Leeper, Heather E., et al.
Publicado: (2015)

Primary Leptomeningeal Oligodendroglioma, IDH-Mutant, 1p/19q-Codeleted
por: Ballester, Leomar Y., et al.
Publicado: (2018)

Patient-derived cells from recurrent tumors that model the evolution of IDH-mutant glioma
por: Jones, Lindsey E, et al.
Publicado: (2020)

The Spatial Patterns and Determinants of Cerebrospinal Fluid Circulation in the Human Brain
por: Nazeri, Arash, et al.
Publicado: (2023)

Radiomics-Based Method for Predicting the Glioma Subtype as Defined by Tumor Grade, IDH Mutation, and 1p/19q Codeletion
por: Li, Yingping, et al.
Publicado: (2022)

IDH mutation status is associated with distinct vascular gene expression signatures in lower-grade gliomas
por: Zhang, Lei, et al.
Publicado: (2018)

Tumor mutational burden predicts survival in patients with low-grade gliomas expressing mutated IDH1
por: Alghamri, Mahmoud S, et al.
Publicado: (2020)

Generation, characterization, and drug sensitivities of 12 patient-derived IDH1-mutant glioma cell cultures
por: Verheul, Cassandra, et al.
Publicado: (2021)

T2/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p/19q non-codeleted gliomas: validity and pathophysiology
por: Foltyn, Martha, et al.
Publicado: (2020)

Monitoring response to a clinically relevant IDH inhibitor in glioma—Hyperpolarized (13)C magnetic resonance spectroscopy approaches
por: Hong, Donghyun, et al.
Publicado: (2023)

Mass spectrometry-based assay for the molecular diagnosis of glioma: concomitant detection of chromosome 1p/19q codeletion, and IDH1, IDH2, and TERT mutation status
por: Pesenti, Chiara, et al.
Publicado: (2017)

Case report: Spinal drop metastasis of IDH-mutant, 1p/19q-codeleted oligodendroglioma
por: Karaman, Ahmet Kursat, et al.
Publicado: (2022)

Glycolytic expression in lower-grade glioma reveals an epigenetic association between IDH mutation status and PDL1/2 expression
por: Givechian, Kevin B, et al.
Publicado: (2020)

The role of DSC MR perfusion in predicting IDH mutation and 1p19q codeletion status in gliomas: meta-analysis and technical considerations
por: Siakallis, Loizos, et al.
Publicado: (2023)

Efficient diagnosis of IDH-mutant gliomas: 1p/19qNET assesses 1p/19q codeletion status using weakly-supervised learning
por: Kim, Gi Jeong, et al.
Publicado: (2023)

A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients
por: Zhu, Zheng, et al.
Publicado: (2020)

Homotopic functional connectivity disruptions in glioma patients are associated with tumor malignancy and overall survival
por: Daniel, Andy G S, et al.
Publicado: (2021)

Structural gray matter alterations in glioblastoma and high-grade glioma—A potential biomarker of survival
por: Lamichhane, Bidhan, et al.
Publicado: (2023)

Proteomics separates adult-type diffuse high-grade gliomas in metabolic subgroups independent of 1p/19q codeletion and across IDH mutational status
por: Bader, Jakob Maximilian, et al.
Publicado: (2022)

How I treat anaplastic glioma without 1p/19q codeletion
por: Berghoff, Anna, et al.
Publicado: (2019)

Effects of 1p/19q Codeletion on Immune Phenotype in Low Grade Glioma
por: Lv, Lei, et al.
Publicado: (2021)

Combined molecular subtyping, grading, and segmentation of glioma using multi-task deep learning
por: van der Voort, Sebastian R, et al.
Publicado: (2022)

Hypoxia and glucose metabolism assessed by FMISO and FDG PET for predicting IDH1 mutation and 1p/19q codeletion status in newly diagnosed malignant gliomas
por: Suzuki, Kenta, et al.
Publicado: (2021)

Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma
por: Kessler, Tobias, et al.
Publicado: (2020)

Case report: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, associated with a germline mutation in PMS2
por: Merchant, Mythili, et al.
Publicado: (2022)

Cystathionine-γ-lyase drives antioxidant defense in cysteine-restricted IDH1-mutant astrocytomas
por: Cano-Galiano, Andrés, et al.
Publicado: (2021)

Bone metastases from a 1p/19q codeleted and IDH1-mutant anaplastic oligodendroglioma: a case report
por: Burgy, Mickaël, et al.
Publicado: (2019)

T(2)-FLAIR Mismatch Sign Is Caused by Long T(1) and T(2) of IDH-mutant, 1p19q Non-codeleted Astrocytoma
por: Kinoshita, Manabu, et al.
Publicado: (2020)

A Multigene Signature Associated with Progression-Free Survival after Treatment for IDH Mutant and 1p/19q Codeleted Oligodendrogliomas
por: Gilhodes, Julia, et al.
Publicado: (2023)

Identification of subsets of IDH-mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risks
por: Li, Kay Ka-Wai, et al.
Publicado: (2019)

Prognostic impact of PDGFRA gain/amplification and MGMT promoter methylation status in patients with IDH wild-type glioblastoma
por: Higa, Nayuta, et al.
Publicado: (2022)

Glioma-associated microglia/macrophages augment tumorigenicity in canine astrocytoma, a naturally occurring model of human glioma
por: Toedebusch, Ryan, et al.
Publicado: (2021)

The T2-FLAIR Mismatch Sign as an Imaging Indicator of IDH-Mutant, 1p/19q Non-Codeleted Lower Grade Gliomas: A Systematic Review and Diagnostic Accuracy Meta-Analysis
por: Adamou, Antonis, et al.
Publicado: (2021)

Longitudinal characteristics of T2-FLAIR mismatch in IDH-mutant astrocytomas: Relation to grade, histopathology, and overall survival in the GLASS-NL cohort
por: van Garderen, Karin A, et al.
Publicado: (2023)

Lack of H3K27 trimethylation is associated with 1p/19q codeletion in diffuse gliomas
por: Filipski, Katharina, et al.
Publicado: (2019)

Overexpression of PSAT1 Gene is a Favorable Prognostic Marker in Lower-Grade Gliomas and Predicts a Favorable Outcome in Patients with IDH1 Mutations and Chromosome 1p19q Codeletion
por: Huang, Shang-Pen, et al.
Publicado: (2019)

TP53, ATRX alterations, and low tumor mutation load feature IDH-wildtype giant cell glioblastoma despite exceptional ultra-mutated tumors
por: Cantero, Diana, et al.
Publicado: (2020)

Improved risk stratification in younger IDH wild-type glioblastoma patients by combining a 4-miRNA signature with MGMT promoter methylation status
por: Unger, Kristian, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k7en7cbhbjidmu44jpql58uvv9